Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2005

View Archived Issues

DA-8159 as a treatment for diabetic erectile dysfunction

CC-4047's mechanism of action remains unclear

NexBio presents Fludase, a novel antiinfluenza recombinant fusion protein / News in Context

Two liposomal lurtotecan regimens induce antitumor effects in relapsed ovarian cancer

CEP-8983 chemosensitizes resistant cells and xenografts

BTS-2 inhibitory activity depends on redox state of tNOX

APF-530 enters phase II for CINV in cancer patients

ISTA seeks green light for phase III trial of combination ophthalmic product

ZLB Behring to study C1-INH concentrate for hereditary angioedema

Inspire reports ophthalmic programs update

Mitsubishi Chemical and Mitsubishi Pharma to form joint holding company

Phase I cancer study of CYT-997 set to begin in May

Prism to market Penwest's PW-2101 in U.S., Canada

Vical's bivalent CMV vaccine set for phase II

ISIS-369645 enters development for asthma

New treatments for cancer covered in recent patents

AS-1410 selected for phase I evaluation against cancer

Complete tumor regression in mice treated with huC242-DM4

First, highly selective 5-HT1D antagonist reported

Novel antihypertensive agents discovered at Bristol-Myers Squibb

Santarus reports new formulations of omeprazole for treating acid-induced gastrointestinal disorders

New antidiabetic agents from Ligand and Takeda

Phase I data confirm MVA-3000 vaccine is safe and immunogenic in healthy volunteers

Evidence suggests a link between sleep disorders and metabolic syndrome in mice

UNBS-1450 demonstrates in vitro and in vivo anticancer activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...